Company intelligence / Profile preview

Thrixen

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

Thrixen’s proprietary diagnostic platform uses engineered protein binders instead of traditional antibodies, enabling rapid (<10 minutes), multiplexed point-of-care tests from finger-prick samples. Clinical trials have shown 99.5% sensitivity for distinguishing bacterial from viral infections, and the company is developing additional tests for Ebola, malaria, and COVID‑19 immunity assessment[4][6].

Therapeutic areas: Infectious Diseases
Modalities: Protein (engineered protein binders)Diagnostic assay (platform)
Industry: Protein Biomarker Diagnostics

Partnerships

BARDA (Biomedical Advanced Research and Development Authority) – partnership to develop multiplex diagnostics for Ebola/malariaSMART (Singapore-MIT Alliance for Research and Technology) – spinout origin/collaboration partnerMedTech Innovator Asia Pacific Accelerator program participant

Beyond the preview

Go deeper on Thrixen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thrixen.

Explore the full profile